Immunocore plans to expand access to KIMMTRAK in 2024

In 2024, the Company plans to expand access to KIMMTRAK to more patients in the United States, Europe and globally, as it continues to establish the therapy as standard of care for the first line treatment for metastatic uveal melanoma in countries where it is launched. As of 2023 year-end, KIMMTRAK has been launched in ten countries and is approved in 38 countries. The Company also continues to enroll patients into a Phase 2/3 clinical trial to investigate the potential of KIMMTRAK in advanced cutaneous melanoma, with randomization expected to be completed in the Phase 2 portion during the third quarter of 2024. Topline data from the Phase 2 portion of the trial is expected to be available by the fourth quarter of 2024. In addition, in 2023, the Company signed an agreement for a European Organisation for Research and Treatment of Cancer-sponsored trial to study KIMMTRAK as adjuvant therapy for uveal melanoma. The Company anticipates that the EORTC will randomize the first patient in the second half of 2024.